文献速递淋巴瘤

理解18F-FDG PET放射组学及其在淋巴瘤中的应用

Understandings 18 FDG PET radiomics and its application to lymphoma.
PubMed 文献 · Br J Haematol · 2025-04-15

本综述探讨放射组学分析在淋巴瘤中的应用现状、标准化进展及其融入临床实践和试验设计的前景。基于基线图像提取的代谢肿瘤体积、总病灶糖酵解及疾病播散和代谢异质性标志物等放射组学特征正成为有力的预后生物标志物。纹理分析作为放射组学最先进的领域,其复杂特征在作为可靠生物标志物采用前仍需进一步标准化和验证。

要点

  • 放射组学可从基线PET图像提取与疾病生物学特征相关的定量特征。
  • 代谢肿瘤体积、总病灶糖酵解及疾病播散和代谢异质性标志物等是有力的预后生物标志物。
  • 纹理分析特征高度复杂,作为可靠生物标志物前需进一步标准化和验证。

核心结论

  • 放射组学特征与临床危险因素及基因组数据结合,在改善临床风险预测方面具有前景。
  • 放射组学标志物与循环肿瘤DNA整合,可能为开发基线和动态风险评分提供全面方法,促进新治疗方案的测试并推进侵袭性淋巴瘤的个体化治疗。

研究设计与样本

  • 本文为综述,探讨放射组学分析在淋巴瘤中的当前状态、标准化进展及其融入临床实践和试验设计的情况。

主要发现

  • PET在淋巴瘤分期和疗效评估中通常采用视觉或半定量评估,其潜在信息大部分未被利用。
  • 放射组学分析采用数学描述符,可从基线图像提取与疾病生物学特征相关的定量特征。
  • 代谢肿瘤体积、总病灶糖酵解及疾病播散和代谢异质性标志物等新兴放射组学特征正成为有力的预后生物标志物。
  • 纹理分析作为放射组学最先进的领域,提供高度复杂的特征,在作为可靠生物标志物采用前需进一步标准化和验证。
  • 将放射组学特征与临床危险因素和基因组数据结合,在改善临床风险预测方面具有前景。

局限性

  • 纹理分析的高度复杂特征在作为可靠生物标志物采用前需进一步标准化和验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The early identification of lymphoma patients who fail front-line treatment is crucial for optimizing disease management. Positron emission tomography, a well-established tool for staging and response evaluation in lymphoma, is typically assessed visually or semiquantitatively, leaving much of its latent information unexploited. Radiomic analysis, which employs mathematical descriptors, can enable the extraction of quantitative features from baseline images that correlate with the disease's biological characteristics. Emerging radiomic features such as metabolic tumour volume, total lesion glycolysis and markers of disease dissemination and metabolic heterogeneity are proving to be powerful prognostic biomarkers in lymphoma. Texture analysis, the most advanced area of radiomics, offers highly complex features that require further standardization and validation before being adopted as reliable biomarkers. Combining radiomic features with clinical risk factors and genomic data holds promising potential for improving clinical risk prediction. This review explores the current state of radiomic analysis, progress towards its standardization and its incorporation into clinical practice and trial designs. The integration of radiomic markers with circulating tumour DNA may provide a comprehensive approach to developing baseline and dynamic risk scores, facilitating the testing of novel treatments and advancing personalized treatment of aggressive lymphomas.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ceriani L, Milan L, Chauvie S, et al. Understandings 18 FDG PET radiomics and its application to lymphoma. Br J Haematol. 2025. PMID: 40230306. doi:10.1111/bjh.20074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。